0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global End-Stage Renal Disease (ESRD) Drugs Market Research Report 2023
Published Date: March 2023
|
Report Code: QYRE-Auto-23R6928
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global End Stage Renal Disease ESRD Drugs Market Insights Forecast to 2028
BUY CHAPTERS

Global End-Stage Renal Disease (ESRD) Drugs Market Research Report 2023

Code: QYRE-Auto-23R6928
Report
March 2023
Pages:86
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Global End-Stage Renal Disease (ESRD) Drugs Market

The global End-Stage Renal Disease (ESRD) Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for End-Stage Renal Disease (ESRD) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for End-Stage Renal Disease (ESRD) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of End-Stage Renal Disease (ESRD) Drugs include CTI BioPharma Corp, Merck & Co Inc, Novartis AG, Prolong Pharmaceuticals LLC and VESSL Therapeutics Ltd, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for End-Stage Renal Disease (ESRD) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding End-Stage Renal Disease (ESRD) Drugs.
The End-Stage Renal Disease (ESRD) Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global End-Stage Renal Disease (ESRD) Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the End-Stage Renal Disease (ESRD) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.

Key Segmentations

By Company

  • CTI BioPharma Corp
  • Merck & Co Inc
  • Novartis AG
  • Prolong Pharmaceuticals LLC
  • VESSL Therapeutics Ltd

Segment by Type

  • Calcium Succinate
  • Mk-3866
  • Pacritinib
  • Sanguinate
  • Tesidolumab
  • Others

Segment by Application

  • Hospital
  • Clinic
  • ICU
  • Others

Consumption by Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Taiwan
  • Indonesia
  • Thailand
  • Malaysia
  • Philippines
  • Vietnam
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of End-Stage Renal Disease (ESRD) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of End-Stage Renal Disease (ESRD) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

Scope of Global End-Stage Renal Disease (ESRD) Drugs Market Report

Report MetricDetails
Report NameGlobal End-Stage Renal Disease (ESRD) Drugs Market
Base Year2022
Forecasted years2023-2029
Forecast unitsUSD
Report coverageRevenue and volume forecast, company share, competitive landscape, growth factors and trends
Geographic regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa
1 End-Stage Renal Disease (ESRD) Drugs Market Overview
1.1 Product Overview and Scope of End-Stage Renal Disease (ESRD) Drugs
1.2 End-Stage Renal Disease (ESRD) Drugs Segment by Type
1.2.1 Global End-Stage Renal Disease (ESRD) Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Calcium Succinate
1.2.3 Mk-3866
1.2.4 Pacritinib
1.2.5 Sanguinate
1.2.6 Tesidolumab
1.2.7 Others
1.3 End-Stage Renal Disease (ESRD) Drugs Segment by Application
1.3.1 Global End-Stage Renal Disease (ESRD) Drugs Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 ICU
1.3.5 Others
1.4 Global End-Stage Renal Disease (ESRD) Drugs Market Size Estimates and Forecasts
1.4.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue 2018-2029
1.4.2 Global End-Stage Renal Disease (ESRD) Drugs Sales 2018-2029
1.4.3 Global End-Stage Renal Disease (ESRD) Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 End-Stage Renal Disease (ESRD) Drugs Market Competition by Manufacturers
2.1 Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global End-Stage Renal Disease (ESRD) Drugs Average Price by Manufacturers (2018-2023)
2.4 Global End-Stage Renal Disease (ESRD) Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of End-Stage Renal Disease (ESRD) Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of End-Stage Renal Disease (ESRD) Drugs, Product Type & Application
2.7 End-Stage Renal Disease (ESRD) Drugs Market Competitive Situation and Trends
2.7.1 End-Stage Renal Disease (ESRD) Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest End-Stage Renal Disease (ESRD) Drugs Players Market Share by Revenue
2.7.3 Global End-Stage Renal Disease (ESRD) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 End-Stage Renal Disease (ESRD) Drugs Retrospective Market Scenario by Region
3.1 Global End-Stage Renal Disease (ESRD) Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global End-Stage Renal Disease (ESRD) Drugs Global End-Stage Renal Disease (ESRD) Drugs Sales by Region: 2018-2029
3.2.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region: 2018-2023
3.2.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region: 2024-2029
3.3 Global End-Stage Renal Disease (ESRD) Drugs Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region: 2018-2029
3.3.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region: 2018-2023
3.3.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region: 2024-2029
3.4 North America End-Stage Renal Disease (ESRD) Drugs Market Facts & Figures by Country
3.4.1 North America End-Stage Renal Disease (ESRD) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2018-2029)
3.4.3 North America End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe End-Stage Renal Disease (ESRD) Drugs Market Facts & Figures by Country
3.5.1 Europe End-Stage Renal Disease (ESRD) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe End-Stage Renal Disease (ESRD) Drugs Sales by Country (2018-2029)
3.5.3 Europe End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific End-Stage Renal Disease (ESRD) Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific End-Stage Renal Disease (ESRD) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific End-Stage Renal Disease (ESRD) Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America End-Stage Renal Disease (ESRD) Drugs Market Facts & Figures by Country
3.7.1 Latin America End-Stage Renal Disease (ESRD) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2018-2029)
3.7.3 Latin America End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2018-2029)
4.1.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2018-2023)
4.1.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2024-2029)
4.1.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Type (2018-2029)
4.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2018-2029)
4.2.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2018-2023)
4.2.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2024-2029)
4.2.3 Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Type (2018-2029)
4.3 Global End-Stage Renal Disease (ESRD) Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2018-2029)
5.1.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2018-2023)
5.1.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2024-2029)
5.1.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application (2018-2029)
5.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2018-2029)
5.2.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2018-2023)
5.2.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2024-2029)
5.2.3 Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Application (2018-2029)
5.3 Global End-Stage Renal Disease (ESRD) Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 CTI BioPharma Corp
6.1.1 CTI BioPharma Corp Corporation Information
6.1.2 CTI BioPharma Corp Description and Business Overview
6.1.3 CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Product Portfolio
6.1.5 CTI BioPharma Corp Recent Developments/Updates
6.2 Merck & Co Inc
6.2.1 Merck & Co Inc Corporation Information
6.2.2 Merck & Co Inc Description and Business Overview
6.2.3 Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Product Portfolio
6.2.5 Merck & Co Inc Recent Developments/Updates
6.3 Novartis AG
6.3.1 Novartis AG Corporation Information
6.3.2 Novartis AG Description and Business Overview
6.3.3 Novartis AG End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Novartis AG End-Stage Renal Disease (ESRD) Drugs Product Portfolio
6.3.5 Novartis AG Recent Developments/Updates
6.4 Prolong Pharmaceuticals LLC
6.4.1 Prolong Pharmaceuticals LLC Corporation Information
6.4.2 Prolong Pharmaceuticals LLC Description and Business Overview
6.4.3 Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Product Portfolio
6.4.5 Prolong Pharmaceuticals LLC Recent Developments/Updates
6.5 VESSL Therapeutics Ltd
6.5.1 VESSL Therapeutics Ltd Corporation Information
6.5.2 VESSL Therapeutics Ltd Description and Business Overview
6.5.3 VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Product Portfolio
6.5.5 VESSL Therapeutics Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 End-Stage Renal Disease (ESRD) Drugs Industry Chain Analysis
7.2 End-Stage Renal Disease (ESRD) Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 End-Stage Renal Disease (ESRD) Drugs Production Mode & Process
7.4 End-Stage Renal Disease (ESRD) Drugs Sales and Marketing
7.4.1 End-Stage Renal Disease (ESRD) Drugs Sales Channels
7.4.2 End-Stage Renal Disease (ESRD) Drugs Distributors
7.5 End-Stage Renal Disease (ESRD) Drugs Customers
8 End-Stage Renal Disease (ESRD) Drugs Market Dynamics
8.1 End-Stage Renal Disease (ESRD) Drugs Industry Trends
8.2 End-Stage Renal Disease (ESRD) Drugs Market Drivers
8.3 End-Stage Renal Disease (ESRD) Drugs Market Challenges
8.4 End-Stage Renal Disease (ESRD) Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
    Table 1. Global End-Stage Renal Disease (ESRD) Drugs Market Value Comparison by Type (2023-2029) & (US$ Million)
    Table 2. Global End-Stage Renal Disease (ESRD) Drugs Market Value Comparison by Application (2023-2029) & (US$ Million)
    Table 3. Global End-Stage Renal Disease (ESRD) Drugs Market Competitive Situation by Manufacturers in 2022
    Table 4. Global End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs) of Key Manufacturers (2018-2023)
    Table 5. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Manufacturers (2018-2023)
    Table 6. Global End-Stage Renal Disease (ESRD) Drugs Revenue (US$ Million) by Manufacturers (2018-2023)
    Table 7. Global End-Stage Renal Disease (ESRD) Drugs Revenue Share by Manufacturers (2018-2023)
    Table 8. Global Market End-Stage Renal Disease (ESRD) Drugs Average Price (USD/Pcs) of Key Manufacturers (2018-2023)
    Table 9. Global Key Players of End-Stage Renal Disease (ESRD) Drugs, Industry Ranking, 2021 VS 2022 VS 2023
    Table 10. Global Key Manufacturers of End-Stage Renal Disease (ESRD) Drugs, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of End-Stage Renal Disease (ESRD) Drugs, Product Type & Application
    Table 12. Global Key Manufacturers of End-Stage Renal Disease (ESRD) Drugs, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global End-Stage Renal Disease (ESRD) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in End-Stage Renal Disease (ESRD) Drugs as of 2022)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global End-Stage Renal Disease (ESRD) Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 17. Global End-Stage Renal Disease (ESRD) Drugs Sales by Region (2018-2023) & (K Pcs)
    Table 18. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Region (2018-2023)
    Table 19. Global End-Stage Renal Disease (ESRD) Drugs Sales by Region (2024-2029) & (K Pcs)
    Table 20. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Region (2024-2029)
    Table 21. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region (2018-2023) & (US$ Million)
    Table 22. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Region (2018-2023)
    Table 23. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region (2024-2029) & (US$ Million)
    Table 24. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Region (2024-2029)
    Table 25. North America End-Stage Renal Disease (ESRD) Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 26. North America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2018-2023) & (K Pcs)
    Table 27. North America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2024-2029) & (K Pcs)
    Table 28. North America End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2018-2023) & (US$ Million)
    Table 29. North America End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2024-2029) & (US$ Million)
    Table 30. Europe End-Stage Renal Disease (ESRD) Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 31. Europe End-Stage Renal Disease (ESRD) Drugs Sales by Country (2018-2023) & (K Pcs)
    Table 32. Europe End-Stage Renal Disease (ESRD) Drugs Sales by Country (2024-2029) & (K Pcs)
    Table 33. Europe End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2018-2023) & (US$ Million)
    Table 34. Europe End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2024-2029) & (US$ Million)
    Table 35. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
    Table 36. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Sales by Region (2018-2023) & (K Pcs)
    Table 37. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Sales by Region (2024-2029) & (K Pcs)
    Table 38. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Revenue by Region (2018-2023) & (US$ Million)
    Table 39. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Revenue by Region (2024-2029) & (US$ Million)
    Table 40. Latin America End-Stage Renal Disease (ESRD) Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 41. Latin America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2018-2023) & (K Pcs)
    Table 42. Latin America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2024-2029) & (K Pcs)
    Table 43. Latin America End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2018-2023) & (US$ Million)
    Table 44. Latin America End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2024-2029) & (US$ Million)
    Table 45. Middle East & Africa End-Stage Renal Disease (ESRD) Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 46. Middle East & Africa End-Stage Renal Disease (ESRD) Drugs Sales by Country (2018-2023) & (K Pcs)
    Table 47. Middle East & Africa End-Stage Renal Disease (ESRD) Drugs Sales by Country (2024-2029) & (K Pcs)
    Table 48. Middle East & Africa End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2018-2023) & (US$ Million)
    Table 49. Middle East & Africa End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2024-2029) & (US$ Million)
    Table 50. Global End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs) by Type (2018-2023)
    Table 51. Global End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs) by Type (2024-2029)
    Table 52. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Type (2018-2023)
    Table 53. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Type (2024-2029)
    Table 54. Global End-Stage Renal Disease (ESRD) Drugs Revenue (US$ Million) by Type (2018-2023)
    Table 55. Global End-Stage Renal Disease (ESRD) Drugs Revenue (US$ Million) by Type (2024-2029)
    Table 56. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Type (2018-2023)
    Table 57. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Type (2024-2029)
    Table 58. Global End-Stage Renal Disease (ESRD) Drugs Price (USD/Pcs) by Type (2018-2023)
    Table 59. Global End-Stage Renal Disease (ESRD) Drugs Price (USD/Pcs) by Type (2024-2029)
    Table 60. Global End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs) by Application (2018-2023)
    Table 61. Global End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs) by Application (2024-2029)
    Table 62. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application (2018-2023)
    Table 63. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application (2024-2029)
    Table 64. Global End-Stage Renal Disease (ESRD) Drugs Revenue (US$ Million) by Application (2018-2023)
    Table 65. Global End-Stage Renal Disease (ESRD) Drugs Revenue (US$ Million) by Application (2024-2029)
    Table 66. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Application (2018-2023)
    Table 67. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Application (2024-2029)
    Table 68. Global End-Stage Renal Disease (ESRD) Drugs Price (USD/Pcs) by Application (2018-2023)
    Table 69. Global End-Stage Renal Disease (ESRD) Drugs Price (USD/Pcs) by Application (2024-2029)
    Table 70. CTI BioPharma Corp Corporation Information
    Table 71. CTI BioPharma Corp Description and Business Overview
    Table 72. CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 73. CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Product
    Table 74. CTI BioPharma Corp Recent Developments/Updates
    Table 75. Merck & Co Inc Corporation Information
    Table 76. Merck & Co Inc Description and Business Overview
    Table 77. Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 78. Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Product
    Table 79. Merck & Co Inc Recent Developments/Updates
    Table 80. Novartis AG Corporation Information
    Table 81. Novartis AG Description and Business Overview
    Table 82. Novartis AG End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 83. Novartis AG End-Stage Renal Disease (ESRD) Drugs Product
    Table 84. Novartis AG Recent Developments/Updates
    Table 85. Prolong Pharmaceuticals LLC Corporation Information
    Table 86. Prolong Pharmaceuticals LLC Description and Business Overview
    Table 87. Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 88. Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Product
    Table 89. Prolong Pharmaceuticals LLC Recent Developments/Updates
    Table 90. VESSL Therapeutics Ltd Corporation Information
    Table 91. VESSL Therapeutics Ltd Description and Business Overview
    Table 92. VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 93. VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Product
    Table 94. VESSL Therapeutics Ltd Recent Developments/Updates
    Table 95. Key Raw Materials Lists
    Table 96. Raw Materials Key Suppliers Lists
    Table 97. End-Stage Renal Disease (ESRD) Drugs Distributors List
    Table 98. End-Stage Renal Disease (ESRD) Drugs Customers List
    Table 99. End-Stage Renal Disease (ESRD) Drugs Market Trends
    Table 100. End-Stage Renal Disease (ESRD) Drugs Market Drivers
    Table 101. End-Stage Renal Disease (ESRD) Drugs Market Challenges
    Table 102. End-Stage Renal Disease (ESRD) Drugs Market Restraints
    Table 103. Research Programs/Design for This Report
    Table 104. Key Data Information from Secondary Sources
    Table 105. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of End-Stage Renal Disease (ESRD) Drugs
    Figure 2. Global End-Stage Renal Disease (ESRD) Drugs Market Value Comparison by Type (2023-2029) & (US$ Million)
    Figure 3. Global End-Stage Renal Disease (ESRD) Drugs Market Share by Type in 2022 & 2029
    Figure 4. Calcium Succinate Product Picture
    Figure 5. Mk-3866 Product Picture
    Figure 6. Pacritinib Product Picture
    Figure 7. Sanguinate Product Picture
    Figure 8. Tesidolumab Product Picture
    Figure 9. Others Product Picture
    Figure 10. Global End-Stage Renal Disease (ESRD) Drugs Market Value Comparison by Application (2023-2029) & (US$ Million)
    Figure 11. Global End-Stage Renal Disease (ESRD) Drugs Market Share by Application in 2022 & 2029
    Figure 12. Hospital
    Figure 13. Clinic
    Figure 14. ICU
    Figure 15. Others
    Figure 16. Global End-Stage Renal Disease (ESRD) Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
    Figure 17. Global End-Stage Renal Disease (ESRD) Drugs Market Size (2018-2029) & (US$ Million)
    Figure 18. Global End-Stage Renal Disease (ESRD) Drugs Sales (2018-2029) & (K Pcs)
    Figure 19. Global End-Stage Renal Disease (ESRD) Drugs Average Price (USD/Pcs) & (2018-2029)
    Figure 20. End-Stage Renal Disease (ESRD) Drugs Report Years Considered
    Figure 21. End-Stage Renal Disease (ESRD) Drugs Sales Share by Manufacturers in 2022
    Figure 22. Global End-Stage Renal Disease (ESRD) Drugs Revenue Share by Manufacturers in 2022
    Figure 23. The Global 5 and 10 Largest End-Stage Renal Disease (ESRD) Drugs Players: Market Share by Revenue in 2022
    Figure 24. End-Stage Renal Disease (ESRD) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
    Figure 25. Global End-Stage Renal Disease (ESRD) Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Figure 26. North America End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Country (2018-2029)
    Figure 27. North America End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Country (2018-2029)
    Figure 28. U.S. End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 29. Canada End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 30. Europe End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Country (2018-2029)
    Figure 31. Europe End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Country (2018-2029)
    Figure 32. Germany End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 33. France End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 34. U.K. End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 35. Italy End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 36. Russia End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 37. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Region (2018-2029)
    Figure 38. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Region (2018-2029)
    Figure 39. China End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 40. Japan End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 41. South Korea End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 42. India End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 43. Australia End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 44. Taiwan End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 45. Indonesia End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 46. Thailand End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 47. Malaysia End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 48. Philippines End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 49. Latin America End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Country (2018-2029)
    Figure 50. Latin America End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Country (2018-2029)
    Figure 51. Mexico End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 52. Brazil End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 53. Argentina End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 54. Middle East & Africa End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Country (2018-2029)
    Figure 55. Middle East & Africa End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Country (2018-2029)
    Figure 56. Turkey End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 57. Saudi Arabia End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 58. UAE End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 59. Global Sales Market Share of End-Stage Renal Disease (ESRD) Drugs by Type (2018-2029)
    Figure 60. Global Revenue Market Share of End-Stage Renal Disease (ESRD) Drugs by Type (2018-2029)
    Figure 61. Global End-Stage Renal Disease (ESRD) Drugs Price (USD/Pcs) by Type (2018-2029)
    Figure 62. Global Sales Market Share of End-Stage Renal Disease (ESRD) Drugs by Application (2018-2029)
    Figure 63. Global Revenue Market Share of End-Stage Renal Disease (ESRD) Drugs by Application (2018-2029)
    Figure 64. Global End-Stage Renal Disease (ESRD) Drugs Price (USD/Pcs) by Application (2018-2029)
    Figure 65. End-Stage Renal Disease (ESRD) Drugs Value Chain
    Figure 66. End-Stage Renal Disease (ESRD) Drugs Production Process
    Figure 67. Channels of Distribution (Direct Vs Distribution)
    Figure 68. Distributors Profiles
    Figure 69. Bottom-up and Top-down Approaches for This Report
    Figure 70. Data Triangulation
    Figure 71. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Accenture

SIMILAR REPORTS